Scientists at the Food and Drug Administration (FDA) have developed a high-throughput method for purifying full-length phosphorothioate and native DNA sequences. This method comprises a modified silica gel that enables capture of DNA sequences functionalized with a novel linker specifically designed for exclusive capture of full-length sequences. This technology has been shown to generate DNA sequences of high purity without the need of expensive equipment and associated accessories. This discovery may improve the availability of pure DNA sequences for clinical and/or synthetic biology applications.
Potential Commercial Applications:
- A high-throughput purification technique for producing small and large quantities of highly pure DNA sequences.
- Cost effective
- High-throughput capabilities
- High purity
In Vitro Data Available
Serge L. Beaucage (FDA)
Andrzej Grajkowski (FDA)
PCT/US2017/039720, filed 6/28/17
US Application 16/312,445, filed 12/21/2018
“Solid-Phase Purification of Synthetic DNA Sequences” J. Org. Chem., 2016, 81 (15), pp 6165–6175. PMID: 27382974
Licensing and Collaborative Research Opportunity Contact:
Parties interested in licensing this technology should contact Charlene Maddox at Charlene.Maddox@fda.hhs.gov.
Charlene Maddox, Ph.D.
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4214
Silver Spring, MD 20993
FDA Reference No.:
August 15, 2017